Atropos Health launched AI model training on its Atropos Evidence Network, a federated healthcare data network containing over 300...

Menarini Group, along with its subsidiary Stemline Therapeutics and research partner MEDSIR, presented research at the San Antonio Breast...

Corcept Therapeutics announced results from its Phase 2 DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS)....

CatalYm’s lead drug candidate, visugromab, a monoclonal antibody targeting the immunosuppressant GDF-15, has shown promising results in a Phase...

Spruce Biosciences announced topline results from two clinical trials, CAHmelia-204 and CAHptain-205, evaluating tildacerfont for congenital adrenal hyperplasia (CAH)....

City of Hope researchers presented groundbreaking studies at the 2024 ASH conference, focusing on innovative treatments for various blood...

Incyte announced positive Phase 3 inMIND trial results for tafasitamab combined with lenalidomide and rituximab in relapsed or refractory...

The Phase 3 inMIND trial showed positive results for tafasitamab combined with lenalidomide and rituximab in treating relapsed or...

Acticor Biotech, a clinical-stage biopharmaceutical company developing glenzocimab for cardiovascular emergencies, faces liquidation as the court-appointed administrator has requested...

The re-election of Donald Trump in 2024 marks the start of a dramatic transformation in healthcare, biotech, and clinical...